SC
CTKB icon

Simcoe Capital’s Cytek Biosciences CTKB Stock Holding History

Simcoe Capital’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-882,113
Closed -$3.85M – 37
2026
Q1 		$3.85M Buy
882,113
+583,652
+196% +$2.76M 3.54% 11
2025
Q4 		$1.51M Buy
+298,461
New +$1.39M 1.42% 31

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Simcoe Capital's CTKB Position: Q2 2026 in Review

Simcoe Capital sold out of Cytek Biosciences (CTKB) in Q2 2026, closing a stake of 882,113 shares — an estimated $3.85M sold.

Simcoe Capital first reported a position in CTKB in Q4 2025 and held it in 2 quarters. The position peaked at $3.85M in Q1 2026. 155 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Simcoe Capital reported no remaining Cytek Biosciences position as of Q2 2026 after selling out during the quarter.
  • Simcoe Capital sold 882,113 Cytek Biosciences shares in Q2 2026, an estimated $3.85M.
  • Simcoe Capital first reported a position in Cytek Biosciences in Q4 2025 and held it in 2 quarters.
  • Simcoe Capital's Cytek Biosciences position peaked at $3.85M in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Simcoe Capital's 13F filing for Q2 2026, filed 6 Aug 2026.